Sunwoda Inside at RE+ 2024: Showcasing Comprehensive Energy Storage Solutions Across the Full Industrial Chain
ANAHEIM, Calif., Sept. 14, 2024 /PRNewswire/ — At RE+ 2024, Sunwoda made a significant impact under the theme “Sunwoda Inside,” underscoring its leadership in providing end-to-end energy storage solutions. With 27 years of experience in battery technology, Sunwoda has developed a
Vertiver Led Capacity Building Workshop at PAU for Nukkad Natak Teams to Promote Regenerative and No-burn Agriculture Ahead of Crop Residue Burning Season
LUDHIANA, India, Sept. 14, 2024 /PRNewswire/ — Theater directors, bhand performers, folk singers and actors, agri scientists, educationists and behavior change experts, gathered at Punjab Agriculture University (PAU) today for a highly immersive Nukkad Natak artists capacity building worksho
Vertiver Led Capacity Building Workshop at PAU for Nukkad Natak Teams to Promote Regenerative and No-burn Agriculture Ahead of Crop Residue Burning Season
LUDHIANA, India, Sept. 14, 2024 /PRNewswire/ — Theater directors, bhand performers, folk singers and actors, agri scientists, educationists and behavior change experts, gathered at Punjab Agriculture University (PAU) today for a highly immersive Nukkad Natak artists capacity building worksho
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipa
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipa
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
HANOI, Vietnam, Sept. 14, 2024 /PRNewswire/ — Mox Capital, a trailblazer in alternative investments with AUM of US$1.4 billion, is announcing its strategic support for a vast array and variety of regional high-potential startups. According to COO Nguyen Dinh Giang, Mox Capital seeks to reinfo
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
HANOI, Vietnam, Sept. 14, 2024 /PRNewswire/ — Mox Capital, a trailblazer in alternative investments with AUM of US$1.4 billion, is announcing its strategic support for a vast array and variety of regional high-potential startups. According to COO Nguyen Dinh Giang, Mox Capital seeks to reinfo
Sineng Electric Expands U.S. Operations with New Service Center in Texas
HOUSTON, Sept. 14, 2024 /PRNewswire/ — Sineng Electric, a global leader in solar and energy storage solutions, has officially inaugurated its North America Service Center in Katy, Texas. This strategic move highlights the company’s commitment to providing superior local support, deliveri
Sineng Electric Expands U.S. Operations with New Service Center in Texas
HOUSTON, Sept. 14, 2024 /PRNewswire/ — Sineng Electric, a global leader in solar and energy storage solutions, has officially inaugurated its North America Service Center in Katy, Texas. This strategic move highlights the company’s commitment to providing superior local support, deliveri
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncol
